Pathogens
Pseudomonas aeruginosa

Pseudomonas aeruginosa

Susceptibilities

General Information

Susceptible Pseudomonas: Cefepime

Difficult to Treat Resistant (DTR) Pseudomonas (defined as non-susceptible to ALL of the following: piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem, ciprofloxacin, and levofloxacin): 

  1. Cystitis: single-dose tobramycin 
  2. Pyelonephritis or complicated UTI: tobramycin 
  3. Infection outside of the urinary tract: ceftolozane/tazobactam

Susceptible Pseudomonas

  • Piperacillin/tazobactam
  • Ceftazidime
  • Meropenem
  • Imipenem
  • Aztreonam
  • Aminoglycosides
  • Fluoroquinolones 

Difficult to Treat Resistant (DTR) Pseudomonas (defined as non-susceptible to ALL of the following: piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem, ciprofloxacin, and levofloxacin):

  1. Cystitis
    1. If confirmed susceptibility: ciprofloxacin, levofloxacin 
    2. Ceftolozane/tazobactam  
       
  2. Pyelonephritis or complicated UTI
    1. If confirmed susceptibility: ciprofloxacin, levofloxacin
    2. Ceftolozane/tazobactam 
       
  3. Infection outside of the urinary tract
    1. Ceftazidime/avibactam 
    2. NDM, IMP, VIM, OXA, KPC carbapenemase identified: cefiderocol

Nonfermenting, aerobic, gram-negative bacillus

  • Ubiquitous, water-associated pathogen
  • Selected for by the administration of non-antipseudomonal antimicrobials
  • Common nosocomial pathogen
  • UTIs
  • Pneumonia (HAP/VAP)
  • Meningitis (post-surgical, TBIs)
  • Bacteremia
  • CLABSIs
  • Complicated ABSSSIs
  • Osteomyelitis
  • May be a colonizer of diseased airways and other sites